Investor Contacts: Olga Guyette, Sr. Director-Investor Relations & Treasury David Trenk, Manager-Investor Relations (781) 356-9763 (203) 733-4987 olga.guyette@haemonetics.com david.trenk@haemonetics.com Media Contact: Jo

Haemonetics Prices Upsized Private Placement

of $600 Million Convertible Senior Notes

BOSTON, MA, May 22, 2024

-- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate

principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering")

to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amount of notes. The offering

is expected to close on May 28, 2024, subject to customary closing conditions. Haemonetics also granted the initial purchasers of

the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to

an additional $100,000,000 principal amount of notes.

The notes will be senior, unsecured obligations of Haemonetics. The

notes will mature on June 1, 2029, unless earlier repurchased, redeemed or converted. Before December 1, 2028, noteholders will

have the right to convert their notes only upon the occurrence of certain events. From and after December 1, 2028, noteholders may

convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the

maturity date. Haemonetics will settle any conversion amounts of the notes up to the $1,000 principal amount of the notes in cash, and

any conversion amounts in excess of the principal amount in cash, shares of Haemonetics' common stock or a combination thereof,

at Haemonetics' election. The initial conversion rate is 8.5385 shares of common stock per $1,000 principal amount of notes, which

represents an initial conversion price of approximately $117.12 per share of common stock. The initial conversion price represents a premium

of approximately 30% over the last reported sale of $90.09 per share of Haemonetics' common stock on May 22, 2024. The conversion

rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will not be redeemable at Haemonetics' election before

June 5, 2027. The notes will be redeemable, in whole or in part, for cash at Haemonetics' option at any time on or after June 5,

2027 and on or before the 50th scheduled trading day immediately before the maturity date, but only if the last reported sale price per

share of Haemonetics' common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will

be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the

If a "fundamental change" (as defined in the indenture

for the notes) occurs, then noteholders may require Haemonetics to repurchase their notes for cash. The repurchase price will be equal

to the principal amount of the notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the applicable

Haemonetics estimates the net proceeds from the offering will be approximately

$584.8 million (or approximately $682.3 million if the initial purchasers fully exercise their option to purchase additional notes), after

deducting the initial purchasers' discounts and commissions and estimated offering expenses.

Haemonetics expects to use the net proceeds from the offering to (i) pay

the approximately $75.6 million (or approximately $88.2 million if the initial purchasers fully exercise their option to purchase additional

notes) cost of the capped call transactions that it entered into as described below, (ii) repurchase for cash $200.0 million in aggregate

principal amount of its 0.00% Convertible Senior Notes due 2026 (the "2026 notes") in privately negotiated transactions entered

into concurrently with the pricing of the notes in the offering, (iii) repay the entirety of the $230.0 million balance on the revolving

credit facility pursuant to Haemonetics' existing credit facility, and (iv) use the remainder of the proceeds for working capital

and other general purposes, which may include additional repurchases of the 2026 notes from time to time following the offering, or the

repayment at maturity, of the 2026 notes.

If the initial purchasers exercise their option to purchase additional

notes, Haemonetics expects to use a portion of the net proceeds from the sale of the additional notes to enter into additional capped

call transactions and the remainder for general corporate purposes, which may include additional repurchases of the 2026 notes from time

to time following the offering, or the repayment at maturity, of the 2026 notes.

In connection with the pricing of the notes, Haemonetics has entered

into privately negotiated capped call transactions with the initial purchasers or their affiliates and other financial institutions (the

"option counterparties"). The capped call transactions will cover, subject to anti-dilution adjustments substantially similar

to those applicable to the notes, the number of shares of Haemonetics' common stock initially underlying the notes. If the initial

purchasers exercise their option to purchase additional notes, Haemonetics expects to enter into additional capped call transactions with

the option counterparties.

The cap price of the capped call transactions will initially be $180.18

per share, which represents a premium of approximately 100% over the last reported sale price of Haemonetics' common stock of $90.09

per share on May 22, 2024, and is subject to certain adjustments under the terms of the capped call transactions.

The capped call transactions are expected generally to reduce or offset

the potential dilution to Haemonetics' common stock upon any conversion of the notes and/or to offset any potential cash payments

Haemonetics is required to make in excess of the principal amount of the converted notes, as the case may be, upon conversion of the notes.

If, however, the market price per share of Haemonetics' common stock, as measured under the terms of the capped call transactions,

exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such

potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.

Haemonetics expects that, in connection with establishing their initial

hedges of the capped call transactions, the option counterparties or their respective affiliates will enter into various derivative transactions

with respect to Haemonetics' common stock and/or purchase shares of Haemonetics' common stock concurrently with or shortly

after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Haemonetics'

common stock or the notes at that time.

In addition, Haemonetics expects that the option counterparties or

their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Haemonetics'

common stock and/or purchasing or selling Haemonetics' common stock or other securities of Haemonetics in secondary market transactions

following the pricing of the notes and from time to time prior to the maturity of the notes (and are likely to do so following any conversion

of the notes, any repurchase of the notes by Haemonetics on any fundamental change repurchase date, any redemption date or any other date

on which the notes are retired by Haemonetics, in each case if Haemonetics exercises its option to terminate the relevant portion of the

capped call transactions, where such termination is at the option of Haemonetics). This activity could also cause or avoid an increase

or a decrease in the market price of Haemonetics' common stock or the notes, which could affect a noteholder's ability to

convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of the notes, it could

affect the number of shares, if any, and value of the consideration that noteholders will receive upon conversion of the notes.

Concurrently with the pricing of the notes in the offering, Haemonetics

entered into privately negotiated transactions with certain holders of the 2026 notes to repurchase, for approximately $185.5 million

in cash, $200.0 million aggregate principal amount of its 2026 notes on terms negotiated with each holder (each, a "note repurchase

transaction"). This press release is not an offer to repurchase the 2026 notes, and the offering of the notes is not contingent upon

the repurchase of the 2026 notes.

In connection with any note repurchase transaction, Haemonetics expects

that holders of the 2026 notes who have agreed to have their 2026 notes repurchased and who have hedged their equity price risk with respect

to such notes (the "hedged holders") will unwind all or part of their hedge positions by buying Haemonetics' common

stock and/or entering into or unwinding various derivative transactions with respect to Haemonetics' common stock. The amount of

Haemonetics' common stock to be purchased by the hedged holders or in connection with such derivative transactions may have been

substantial in relation to the historical average daily trading volume of Haemonetics' common stock. This activity by the hedged

holders could increase (or reduce the size of any decrease in) the market price of Haemonetics' common stock, including concurrently

with the pricing of the notes, and may have resulted in a higher effective conversion price of the notes.

Additionally, in connection with the issuance of the 2026 notes, Haemonetics

entered into capped call transactions (the "existing option transactions") with certain financial institutions. Haemonetics

does not intend to unwind or terminate any of the existing option transactions in connection with these note repurchase transactions.

The notes will be sold only to persons reasonably believed to be qualified

institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock

issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws,

and unless so registered, the notes and any such shares cannot be offered or sold except pursuant to an applicable exemption from, or

in a transaction not subject to, such registration requirements. This press release does not constitute an offer to sell, or the solicitation

of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any offer or sale

of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

Haemonetics is a global healthcare company dedicated to providing a

suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.

Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion